O

Option Care Health

Largest independent home infusion therapy provider

Territory Sales Leader

Full-TimeUpdated on 10/23/2026
$149.5k - $249.2k
Junior, Mid
Bachelor's, MBA
Fresno, CA, USA+2 moreMore locations: Sacramento, CA, USA | Hayward, CA, USA
In PersonTravel at least 60% of the time for business, within and outside the state.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree, ideally in business or a clinical field, and at least 1–2 years of previous business-to-business healthcare or medical-related sales leadership experience, or a high school diploma and/or some college with 5 years of related business-to-business healthcare or medical sales experience.
  • Experience analyzing and reporting sales data to identify issues, trends, or exceptions, improve results, and find solutions.
  • Experience using and teaching time-management skills such as prioritizing, organizing, and tracking project plans and meeting deadlines for multiple projects with varying completion dates.
  • Experience developing and delivering presentations within the organization and externally to customers such as medical directors, heads of case management, and C-suite executives.
Responsibilities
  • Drive sales with the assigned team by partnering with operations counterparts to build market growth plans, working across business units, leadership, and sales teams to set goals and develop sales forecasts for each assigned territory, and ensuring alignment with national business unit and specialty enterprise objectives.
  • Partner with operations and payer counterparts to build regional strategic market plans that increase market penetration; assist in developing and implementing promotional activities; and engage cross-functionally to align sales efforts with branches, sales personnel, and branch personnel.
  • Develop Account Executives to create and deliver sales presentations and lead consultative sales discussions.
  • Lead by example by demonstrating success in creating new business within the assigned area.
  • Develop a highly productive account team of Account Executives by actively engaging in selling opportunities to coach and provide developmental feedback.
  • Maintain strong relationships with branch management so sales efforts are supported by branch service and aligned with branch capabilities; partner with operations to resolve customer issues.
  • Monitor competitors, industry, and sales trends in the assigned area; analyze input from various sources to create initiatives; and develop business plans for new initiatives covering market-entry strategy, financial analysis and projected costs, timelines, and necessary resources.
  • Monitor the assigned sales team's activity to ensure focus on priority growth targets identified by management and analytics; help Account Executives, Care Transition Specialists, and Care Transition Coordinators prioritize opportunities; provide productivity analysis and feedback on overall and key-customer performance; and identify training and development opportunities.
  • Serve as an expert for the assigned team on local market dynamics, including payer issues, state and government regulations, and provider payment issues, and on the complex disease states served by the company, including anti-infectives, nutrition, heart failure, immunological disorders, bleeding disorders, and transplant; coach and develop the team in these areas.
  • Hire staff, recommend pay increases, manage sales performance, conduct performance reviews, train and develop staff, estimate personnel needs, assign work, and interpret and ensure consistent application of organizational policies.
  • Identify opportunities and develop relationships with alliance partners outside the company in the assigned territory to increase business; develop plans to achieve goals for targeted opportunities.
  • Comply with accreditation, legal, regulatory, and safety requirements and ensure the team does the same.
  • Delegate work and hold account executives, clinical liaisons, and operational partners accountable to focus on growth opportunities and build team competency and accountability.
  • Act as a player-coach who can step in when needed to prospect and close business.
Desired Qualifications
  • An MBA in Business Administration and at least 4 years of pharmaceutical or healthcare sales experience.
  • Prior experience selling strategic solutions, including specialty products and/or services, to hospitals, health systems, and medical groups.
  • Infusion or healthcare service experience in anti-infective, nutrition, immunology/neurology, oncology, or transplant therapeutic areas.
  • A basic understanding of billing and reimbursement procedures for hospitals, medical offices, and Medicare Part B and Part D benefits.
  • One year of experience directly managing people, including hiring, developing, motivating, and directing people, and experience leading team efforts within highly matrixed organizations.

About the company

Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bannockburn, Illinois

Founded

1979

Get referred to Option Care Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 29, 2026 Q2 revenue reached $1.44 billion, while acute therapy and IG Neuro strengthened.
  • Management stabilized CID patient census in Q2 2026 and kept full-year revenue guidance unchanged.
  • The company repurchased $150 million in Q2 2026, signaling confidence and shareholder-return capacity.

What critics are saying

  • August 2026 guidance still bakes in a 600-basis-point CID revenue headwind and $55 million gross profit hit.
  • July 29, 2026 Q2 buyback of $150 million masks weak top-line momentum and analyst skepticism.
  • Biosimilar erosion and payer reverification pressure can permanently shrink chronic volumes if retention stays broken.

What makes Option Care Health unique

  • Option Care Health leads U.S. independent home and alternate-site infusion, with nationwide clinician density.
  • Its payer, biopharma, and prescriber relationships create switching costs across chronic and acute therapies.
  • August 27, 2026 guidance shows durable cash generation, with at least $320 million operating cash flow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Time Off
  • Bonding Time Off
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Health Savings Account/Flexible Spending Account
  • Flexible Spending Accounts
  • Tuition Reimbursement
  • Family Support
  • Mental Health Support

Company News

AD HOC NEWS
Oct 15th, 2026
McKesson commits $1.4B for 49% stake in Option Care at $5.8B valuation

McKesson will invest $1.4 billion for a 49% minority stake in Option Care Health, under an agreement announced on October 6, 2026. The deal values Option Care at an enterprise value of $5.8 billion. Clayton, Dubilier & Rice will hold about 51%. Option Care will stay separately managed, while McKesson keeps a framework to acquire the remaining interest later, subject to conditions and regulatory approvals. In its first fiscal 2027 quarter, McKesson reported revenue of $105.38 billion, up 7.7% year on year, and adjusted earnings per share of $9.93. It will report second-quarter results on November 4, 2026.

Yahoo Finance
Oct 6th, 2026
McKesson and Clayton Dubilier & Rice near $5B deal to acquire Option Care Health

Option Care Health shares jumped 33.2% in pre-market trading after the Financial Times reported McKesson and Clayton Dubilier & Rice are nearing a transaction valued at over $5 billion to acquire the alternate site health provider. According to the report, the deal would involve the two firms partnering to buy the infusion services provider, which they view as undervalued. Large-scale buyout discussions typically drive market optimism as investors anticipate acquisition premiums. The move is significant for Option Care Health, whose shares have experienced 13 movements greater than 5% over the past year. At $31.03 per share, the stock is trading 15.2% below its 52-week high but remains down 3.8% year-to-date.

Central Charts
Oct 6th, 2026
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health

CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today that they have

Yahoo Finance
Jul 29th, 2026
Option Care Health Q2 beats expectations with $1.4B revenue, narrows full-year guidance

Option Care Health reported second-quarter 2026 results that exceeded expectations. Revenue rose 7% sequentially to $1.4 billion, whilst adjusted EBITDA increased 12% to $117.5 million and adjusted EPS reached $0.45. Operating cash flow totalled $184 million. Acute therapies posted high-single-digit organic growth, while chronic revenue improved sequentially as the CID portfolio began to stabilise. However, CID-related pressure is expected to reduce 2026 revenue by roughly 600 basis points and gross profit by $55 million. The home and alternate-site infusion provider maintained its full-year revenue guidance at $5.675 billion to $5.775 billion. Adjusted EBITDA guidance was narrowed to $480 million to $495 million, and adjusted EPS guidance to $1.85 to $1.92. The company repurchased $150 million of shares, nearly 5% of shares outstanding.

Yahoo Finance
Jul 29th, 2026
Option Care Health reports $1.44B Q2 revenue, up 1.9%, and raises $150M share buyback

Option Care Health, the largest independent provider of home and alternate site infusion services in the US, reported second quarter 2026 results. Net revenue reached $1.44 billion, up 1.9% year-over-year. The company posted net income of $53.9 million, up 6.7%, with diluted earnings per share of $0.35, up 12.9%. Adjusted EBITDA grew 3.0% to $117.5 million. The company repurchased $150 million of outstanding shares during the quarter. For full year 2026, Option Care Health expects net revenue between $5.68 billion and $5.78 billion, with adjusted diluted earnings per share of $1.85 to $1.92. The company forecasts adjusted EBITDA of $480 million to $495 million and operating cash flow of at least $320 million.